Table 3.
Changes in HRV indexes in PAH patients with sildenafil therapy
| Parameter |
PAH |
Control | ||
|---|---|---|---|---|
| Before treatment | After treatment | |||
| Supine position | SDNN, ms | 18.3±10.1a | 32.0±16.5 | 44.3±9.0 |
| RMSSD, ms | 12.9±11.2a | 21.4±23.7a | 36.5±11.7 | |
| pNN50,% | 1.66±3.62 | 6.9±14.4 | 13.6±12.0 | |
| LF/HF | 3.7±2.2 | 3.6±2.6 | 2.7±4.2 | |
| Orthostasis | SDNN, ms | 40.9±16.5 | 45.9±17.0 | 45.8±17.7 |
| RMSSD, ms | 19.4±16.2 | 14.1±7.1 | 19.6±9.8 | |
| pNN50,% | 3.92±8.05 | 1.2±1.4 | 3.0±3.6 | |
| LF/HF | 8.0±4.5 | 7.2±3.1 | 5.8±3.3 | |
Note: data presented as mean ± SD;
a
Difference significant comparing to control group.